ResearchHub | Open Science Community

Sherilyn Tuazon

Author with expertise in Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia

Achievements

This user has not unlocked any achievements yet.

Key Stats

Upvotes received:

Publications:

(0% Open Access)

Cited by:

h-index:

i10-index:

Reputation

Biology

< 1%

Chemistry

< 1%

Economics

< 1%

How is this calculated?

Publications

CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Oliver Press et al.Sep 1, 2024

Paper

Save

Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Oliver Press et al.Sep 1, 2024

Paper

Save

Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Oliver Press et al.Sep 1, 2024

Paper

Save

Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Andrew Portuguese et al.Nov 5, 2024

Paper

Save

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

William Wierda et al.Nov 5, 2024

Paper

Save

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Tanya Siddiqi et al.Nov 5, 2024

Paper

Save